FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease
The US Food and Drug Administration (FDA) issued supplemental approval of a gene therapy for patients aged 2 years or older with either sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.